Tenderwize
Zurück zur Suche

Open-house rebate agreements for Sevelamer hydrochloride

AOK Rheinland-Pfalz/Saarland - Die Gesundheitskasse·Eisenberg, Germany·Deadline Nov 30, 2027 · 462 days left·Open·Supplies
Originaltitel der Bekanntmachung

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge zum Wirkstoff Sevelamer hydrochlorid, ATC V03AE02

63/100

Opportunity Score

Needs reviewMedium complexity
SuppliesOpen
Warum diese Bewertung?

Chance

63 / 100

Komplexität

58 / 100

Risikofaktoren

Structured data says electronic submission is not allowed, while the extracted notice text allows electronic submission...

The buyer reserves the right to replace open-house agreements with exclusive rebate agreements during the term, which w...

Tiefe Portfolioanalyse

Tiefe Analyse der Unternehmenspassung

Verwendet:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Überblick

Moderate opportunity

Wichtige Fakten

  • Supplies contract
  • 1 lot
  • Duration until Jan 2028
  • Supply/rebate-contract model for pharmaceutical products containing Sevelamer hydrochloride (ATC V03AE02).
  • Open-house approach with non-exclusive access for all interested pharmaceutical companies meeting the stated conditions.
Vollständige Zusammenfassung anzeigen

Open-house supply arrangement for the pharmaceutical ingredient Sevelamer hydrochloride (ATC V03AE02) offered by AOK Rheinland-Pfalz/Saarland. It is a non-exclusive framework-like contract model with no selection decision and equal conditions for all qualifying pharmaceutical companies. The notice states that children’s medicines on the BfArM list under § 35(5a) SGB V are excluded. Contracts run from 01.02.2026 to 31.01.2028 at the latest, with monthly entry possible. Electronic submission is not allowed in the notice metadata, but the document text allows either handwritten original submission by post or electronic submission with qualified electronic signature by email.

Risiken

Structured data says electronic submission is not allowed, while the extracted notice text allows electronic submission...

The buyer reserves the right to replace open-house agreements with exclusive rebate agreements during the term, which w...

Analyse kann unvollständig sein

Nur ein Teil der Vergabeunterlagen wurde analysiert. Weitere Anforderungen, Zertifikate oder Einreichungsdokumente können in den übrigen Unterlagen enthalten sein.

Wichtige Anforderungen

Technical

  • Products must be authorized and marketable in Germany.

Eligibility

  • Only pharmaceutical companies are eligible to become contract partners.

Administrative

  • If a product is not yet listed in Lauer-Taxe at submission time, an AMIce public-section extract must be provided.

Auftraggeber

Lose (1)

LOT-0001

Open-house rebate agreements for Sevelamer hydrochloride

Open-house, non-exclusive rebate agreements for medicines containing Sevelamer hydrochloride (ATC V03AE02). Scope is limited to eligible pharmaceutical products; children’s medicines on the BfArM list are excluded. Contract terms are standardized and no individual negotiations are conducted. This lot information is explicit in the structured data and document text.

SuppliesEU fundedElectronic submission

Ort

Eisenberg, Germany

Dauer

Jan 2026 - Jan 2028

Kategorie

Pharmaceutical products

Frist

Deadline Nov 30, 2027

Vergabedetails

Veröffentlichungsdatum
09 Dec 2025
Sprachen
German

Referenzmetadaten

Rechtsgrundlage
32014L0024

Referenz-IDs

Ausschreibungs-ID
817811-2025

Dokumente (1)

Ähnliche Ausschreibungen